Detalhe da pesquisa
1.
A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.
Cancer
; 129(2): 264-271, 2023 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-36420773
2.
Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
J Natl Compr Canc Netw
; 20(12): 1316-1320, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-36509071
3.
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
Cancer
; 126(19): 4353-4361, 2020 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32697352
4.
A multi-center phase II trial evaluating the efficacy of palbociclib in combination with carboplatin for the treatment of unresectable recurrent or metastatic head and neck squamous cell carcinoma.
Invest New Drugs
; 38(5): 1550-1558, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31981071
5.
Targeting multiple angiogenic pathways simultaneously: experience with nintedanib in non-small-cell lung cancer.
Future Oncol
; 10(7): 1167-73, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24947258
6.
Comparison of PD-L1 IHC 22C3 PharmDx Combined Positive Score (CPS) in Primary Versus Metastatic Nodal Squamous Cell Carcinomas of the Head and Neck: Is There a Significant Difference?
Appl Immunohistochem Mol Morphol
; 31(8): 550-554, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37358840
7.
Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?
Future Oncol
; 13(28): 2503-2505, 2017 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29168656
8.
Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 22(4): 274-281, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-33610454
9.
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
J Immunother Cancer
; 9(7)2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34301809
10.
Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
Clin Lung Cancer
; 21(3): 288-293, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-32143966
11.
Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.
Hematol Oncol Clin North Am
; 31(1): 71-81, 2017 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27912835
12.
Optimal Duration of Maintenance Checkpoint Inhibitor Therapy in Patients With Advanced NSCLC.
JCO Oncol Pract
; 17(8): 472-474, 2021 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33939474
13.
The shifting paradigm of biomarker-driven care in advanced non-small cell lung cancer (NSCLC).
Transl Lung Cancer Res
; 8(4): 539-542, 2019 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-31555527
14.
TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate Cancer.
Clin Genitourin Cancer
; 15(3): e489-e491, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28216280